Abstract
Multiple myeloma is an incurable B cell neoplasm caused by the monoclonal expansion of malignant plasma cells in the bone marrow, often resulting in devastating bone disease. For over 2 decades bisphosphonates have been successfully used to treat the tumourinduced bone disease associated with multiple myeloma. This review will focus on preclinical studies and investigations in patients with multiple myeloma that have led to our current understanding of the mechanisms of action of bisphosphonates in myeloma bone disease. Major advances in the use of bisphosphonates, including findings that they may have additional benefits such as anti-tumour effects and promoting patient survival will be discussed.
Keywords: Bisphosphonates, myeloma, anti-resorptive, anti-tumour, bone, osteoclasts, osteolytic lesions, Multiple Myeloma, M-spike, M-protein, Bence-Jones Protein, lymphatohaemopoietic cancer, Osteoclast-derived molecules, dickkopf-1 (DKK1), frizzled-related protein (sFRP)-2, myeloma-derived DKK1, MM-derived osteoclasts, anti-DKK1, OSTEOCLAST INHIBITION, clodronate (CLOD), etidronate (ETID), protein prenylation, bone mineral density (BMD), Anti-Tumour Effects, anti-resorptive potency, SCID-hu model, Angiogenesis, Bisphosphoante-Associated Osteonecrosis of the Jaw (BONJ), vascular insufficiency, B-cell activating factor, Hepatocyte growth factor, Interleukin 1 alpha
Current Pharmaceutical Design
Title: Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Volume: 16 Issue: 27
Author(s): M. A. Lawson, J. Ashcroft and P. I. Croucher
Affiliation:
Keywords: Bisphosphonates, myeloma, anti-resorptive, anti-tumour, bone, osteoclasts, osteolytic lesions, Multiple Myeloma, M-spike, M-protein, Bence-Jones Protein, lymphatohaemopoietic cancer, Osteoclast-derived molecules, dickkopf-1 (DKK1), frizzled-related protein (sFRP)-2, myeloma-derived DKK1, MM-derived osteoclasts, anti-DKK1, OSTEOCLAST INHIBITION, clodronate (CLOD), etidronate (ETID), protein prenylation, bone mineral density (BMD), Anti-Tumour Effects, anti-resorptive potency, SCID-hu model, Angiogenesis, Bisphosphoante-Associated Osteonecrosis of the Jaw (BONJ), vascular insufficiency, B-cell activating factor, Hepatocyte growth factor, Interleukin 1 alpha
Abstract: Multiple myeloma is an incurable B cell neoplasm caused by the monoclonal expansion of malignant plasma cells in the bone marrow, often resulting in devastating bone disease. For over 2 decades bisphosphonates have been successfully used to treat the tumourinduced bone disease associated with multiple myeloma. This review will focus on preclinical studies and investigations in patients with multiple myeloma that have led to our current understanding of the mechanisms of action of bisphosphonates in myeloma bone disease. Major advances in the use of bisphosphonates, including findings that they may have additional benefits such as anti-tumour effects and promoting patient survival will be discussed.
Export Options
About this article
Cite this article as:
A. Lawson M., Ashcroft J. and I. Croucher P., Bisphosphonate Therapy in the Treatment of Multiple Myeloma, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563608
DOI https://dx.doi.org/10.2174/138161210793563608 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preclinical Studies of PROTACs in Hematological Malignancies
Cardiovascular & Hematological Disorders-Drug Targets The Impact of Thrombopoietin on Clinical Practice
Current Pharmaceutical Design Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Analytical Methods of Bioactive Metabolites Produced by Plants and Microorganisms
Current Pharmaceutical Analysis Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Role of Growth Factors in the Pathogenesis of Tissue Fibrosis in Systemic Sclerosis
Current Rheumatology Reviews AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate
Anti-Cancer Agents in Medicinal Chemistry The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Measurement of Vitamin K Metabolites in Neonatal Faecal Matter by HPLC with Electrochemical Detection
Current Chromatography Nucleoside Transport as a Potential Target for Chemotherapy in Malaria
Current Pharmaceutical Design Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia
Current Drug Targets Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology miRNA: Small Molecules as Potential Novel Biomarkers in Cancer
Current Medicinal Chemistry Computational Peptidology: A New and Promising Approach to Therapeutic Peptide Design
Current Medicinal Chemistry